Special Issue "Advances in Cancer Therapeutics"
Deadline for manuscript submissions: 20 September 2024 | Viewed by 46409
Interests: cancer; cancer drug resistance; anti-angiogenesis therapy; immunotherapy
Interests: optogenetics; synthetic biology; immunotherapy; calcium signaling; CAR T cell therapy; epigenetics
Special Issues, Collections and Topics in MDPI journals
Cancer is the second leading cause of death worldwide, and drug therapy remains one of the most common and effective means of cancer treatment. Anti-cancer drug therapy includes chemotherapy, targeted therapy, anti-angiogenesis therapy, endocrine therapy, and immunotherapy. Cancer drug resistance is a common cause of cancer treatment failure, which is responsible for up to 90% of cancer-related deaths. Nevertheless, with in-depth research and drug development, more and more cancer patients still benefit from drug therapy. In particular, the use of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of cancer; some cancer patients could even have a complete response after ICI treatment. Thus, it is urgent to screen novel targets for appropriate use guidance, as well as to select appropriate drug combinations to combat drug resistance.
We are pleased to invite you to contribute to this Special Issue. The aim of this Special Issue is to build a community of cancer researchers and readers to discuss the latest research and develop new ideas and research directions in developing effective cancer drug therapy. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
This Special Issue will focus on the optimization of cancer drug therapy through the exploration of biomarkers that could guide the use of anti-cancer drugs and help to identify the signaling pathways that participate in drug resistance as well as the drug combinations that are more effective in cancer treatment. Our ultimate goal is to achieve individualized treatment of cancer patients with precision medicine.
We look forward to receiving your contributions.
Dr. Han Weidong
Dr. Yubin Zhou
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug resistance
- Immune checkpoint inhibitors (ICIs)
- molecular mechanisms
- cancer immunotherapy
- signaling pathways